Viridian Therapeutics 获得 Needham & Company LLC 的“买入”评级。 Viridian Therapeutics Earns “Buy” Rating from Needham & Company LLC.
根据周三的一份研究报告，Viridian Therapeutics（纳斯达克股票代码：VRDN）获得 Needham & Company LLC 的“买入”评级以及 30 美元的目标价。 Viridian Therapeutics (NASDAQ: VRDN) received a "Buy" rating from Needham & Company LLC, along with a $30 target price, according to a research note on Wednesday. 其他公司也发布了该股的研究报告，奥本海默将目标价提高至 36 美元，HC Wainwright 将目标价设定为 37 美元。 Other firms have also issued research reports on the stock, with Oppenheimer increasing their target price to $36 and HC Wainwright setting a $37 target. 加拿大皇家银行和韦德布什银行也重申了该公司的“跑赢大盘”评级。 Royal Bank of Canada and Wedbush also reaffirmed "outperform" ratings for the company.